A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980 · Completed

Last updated 2026-05-28

This clinical trial compares how well different doses of orforglipron (a medication) in tablet and capsule forms are absorbed in healthy adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 533 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2024-06 · est. completion 2025-06

Where 7 sites · United States

What this study is testing ClinicalTrials.gov NCT06440980 ↗

Description as written by the study sponsor.

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally

Main thing measured	Part B: Pharmacokinetics (PK): Steady-state area under the concentration versus time curve from time 0 to τ hour time point AUC(0-τ) of Orforglipron capsule at test dose levels 2,3,4 and 6 along with the corresponding tablet dose strengths
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Obese, Overweight, Obesity
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06440980 ↗